^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
02/16/2021
Excerpt:
High-Grade B-Cell Lymphomas with Translocations of MYC and BCL2 and/or BCL6 (Double/Triple Hit Lymphoma): Lisocabtagene maraleucel was added as a category 2A recommendation for relapsed/refractory disease.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Published date:
09/01/2020
Excerpt:
Eligible histological subgroups included diffuse large B-cell lymphoma, high-grade B-cell lymphoma with rearrangements of MYC and either BCL2, BCL6, or both (double-hit or triple-hit lymphoma)...an objective response was achieved by 186 (73%, 95% CI 66·8–78·0) patients and a complete response by 136 (53%, 46·8–59·4)....Use of liso-cel resulted in a high objective response rate, with a low incidence of grade 3 or worse cytokine release syndrome...
DOI:
10.1016/S0140-6736(20)31366-0